Merck announced that Jakob Hoppe will become the new Chief Financial Officer for the Healthcare business sector (CFO Healthcare) effective January 1, 2022.
Merck, a leading science and technology company, today announced that Jakob Hoppe will become the new Chief Financial Officer for the Healthcare business sector (CFO Healthcare) effective January 1, 2022. In this role, he will report to Marcus Kuhnert, Member of the Executive Board and Chief Financial Officer of Merck. Hoppe succeeds Andreas Stickler, who will leave the company at his own request on 31 December 2021 to pursue new professional challenges.
"I would like to expressly thank Andreas Stickler for his dedication, leadership and outstanding contribution to the success of our company. During his time at Merck, he not only contributed as a highly valued member of the Finance and Healthcare leadership teams and a very experienced finance expert, but also made a significant contribution to the successful transformation of our Healthcare business," said Marcus Kuhnert. "At the same time, I am very pleased that we were able to promote Jakob Hoppe, a talent from our own ranks, to the new Healthcare CFO," Kuhnert continued.
Andreas Stickler joined Merck in 2002 as Financial Controller for the Europe region as well as the Oncology Business Unit and subsequently held other important management positions. From 2008 to 2015, as Head of M&A, he drove key strategic acquisitions (e.g. Serono, Millipore, Sigma Aldrich) that were crucial for Merck's future profitable growth. In 2015, Andreas Stickler took over as CFO of Healthcare Controlling, followed by additional responsibilities as Head of Strategy, Business Development, Portfolio Management and Digital & Data in 2019.
Jakob Hoppe joined Merck's finance division (Group Finance) in 2007 as part of the graduate trainee programme. Since then, he has held various positions of increasing strategic relevance and scope within Group Finance, most recently as Head of Controlling, Marketing and Strategy Healthcare. There he also took over the interim management of the Immunology Business Unit for more than a year. In his future role, he will serve on the CFO Council and the Healthcare Executive Committee.